Jnter'l Pre. Exam Rar ATENT COOPERATION TRL TY

From the INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:

FALCOFF,Monte L. HARNESS, DICKEY & PIERCE, P.L.C. P.O. Box 828 Bloomfield Hills, MI 48303 ETATS-UNIS D'AMERIQUE PCT

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(PCT Rule 71.1)

IMPORTANT NOTIFICATION

Date of mailing

(day/month/year)

04.10.2005

Applicant's or agent's file reference 6550-072/POA

International application No.

PCT/US2004/021451

International filing date (day/month/year) Priority dat

02.07.2004

Priority date (day/month/year) 03.07.2003

Applicant

BOARD OF TRUSTEES OPERATING MICHIGAN STATE ...

- The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary report on patentability and its annexes, if any, established on the international application.
- 2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
- 3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary report on patentability. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

The applicant's attention is drawn to Article 33(5), which provides that the criteria of novelty, inventive step and industrial applicability described in Article 33(2) to (4) merely serve the purposes of international preliminary examination and that "any Contracting State may apply additional or different criteria for the purposes of deciding whether, in that State, the claimed inventions is patentable or not" (see also Article 27(5)). Such additional criteria may relate, for example, to exemptions from patentability, requirements for enabling disclosure, clarity and support for the claims.

Name and malling address of the international preliminary examining authority:

<u>)</u>

European Patent Office - P.B. 5818 Patentlaan 2 NL-2280 HV Rijswijk - Pays Bas Tel. +31 70 340 - 2040 Tx: 31 651 epo nl Fax: +31 70 340 - 3016 Authorized Officer

Bröcker-Tazelaar, G

Tel. +31 70 340-2103



PATENT COOPERATION TRATY

PCT

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 6550-072/POA	FOR FURTHER A	CTION	See Form PCT/IPEA/416	
International application No. PCT/US2004/021451	International filing date 02.07.2004	(day/month/year)	Priority date (day/month/year) 03.07.2003	
International Patent Classification (IPC) or national classification and IPC C12N15/82, C07K14/085				
Applicant BOARD OF TRUSTEES OPERATING MICHIGAN STATE				
 This report is the international preliminary examination report, established by this International Preliminary Examining Authority under Article 35 and transmitted to the applicant according to Article 36. 				
2. This REPORT consists of a total of 6 sheets, including this cover sheet.				
3. This report is also accompanied by ANNEXES, comprising:				
a. sent to the applicant and to the International Bureau) a total of sheets, as follows:				
sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions).				
sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.				
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)), containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).				
4. This report contains indications relating to the following items:				
☐ Box No. I Basis of the opinion				
☐ Box No. II Priority				
Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability				
 □ Box No. IV Lack of unity of invention ☑ Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial 				
⊠ Box No. V Reasoned state applicability; cita	ment under Article 35(2 ations and explanations	 with regard to novelty, supporting such statem 	inventive step or industrial ent	
Box No. VI Certain docume	ents cited			
	in the international app			
☐ Box No. VIII Certain observa	tions on the internation	al application		
Date of submission of the demand		Date of completion of this	report	
01.02.2005		04.10.2005		
Name and mailing address of the international		Authorized Officer	na s Potente	
Tel. +31 70 340 - 2040 Tx: 31 651 epo nl		Oderwald, H Telephone No. +31 70 34	O-	

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/US2004/021451

	Box No. I Ba	sis of the report
1.	With regard to filed, unless of	the language , this report is based on the international application in the language in which it wa herwise indicated under this item.
		t is based on translations from the original language into the following language , le language of a translation furnished for the purposes of:
	☐ publica	tional search (under Rules 12.3 and 23.1(b)) tion of the international application (under Rule 12.4) tional preliminary examination (under Rules 55.2 and/or 55.3)
2.	have been furn	the elements* of the international application, this report is based on <i>(replacement sheets which ished to the receiving Office in response to an invitation under Article 14 are referred to in this nally filed" and are not annexed to this report):</i>
	Description, Pa	ges
	1-45	as originally filed
	Sequence listin	gs part of the description, Pages
	1-6	as originally filed
	Claims, Numbe	rs
	1-235	as originally filed
	Drawings, Shee	ets
	1/6-6/6	as originally filed
	⊠ a sequenc	e listing and/or any related table(s) - see Supplemental Box Relating to Sequence Listing
3.	☐ the des☐ the clai☐ the dra☐ the sec	dments have resulted in the cancellation of: cription, pages ms, Nos. wings, sheets/figs juence listing (specify): lle(s) related to sequence listing (specify):
4.	had not been n Supplemental I the des the clai the dra the sec	wings, sheets/figs juence listing <i>(specify)</i> :
	•	ele(s) related to sequence listing (specify): 4 applies, some or all of these sheets may be marked "superseded."

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/US2004/021451

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N) Yes: Claims 1-235

No: Claims

Inventive step (IS) Yes: Claims 1-235

No: Claims

Industrial applicability (IA) Yes: Claims 1-235

No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/US2004/021451

Supplemental Box relating to Sequence Listing				
Continuation of Box I, item 2:				
 With regard to any nucleotide and/or amino acid sequence disclosed in the international application and necessary to the claimed invention, this report has been established on the basis of: 				
a. type of material:				
☑ a sequence listing				
☐ table(s) related to the sequence listing				
b. format of material:				
☑ in computer readable form				
c. time of filing/furnishing:				
☐ contained in the international application as filed				
☐ filed together with the international application in computer readable form				
☑ furnished subsequently to this Authority for the purposes of search and/or examination				
☐ received by this Authority as an amendment on				
2. In addition, in the case that more than one version or copy of a sequence listing and/or table(s) relating thereto has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as file as appropriate, were furnished.				
dditional observations, if necessary:				

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

- D1: WO 02/12522 A (THE UNIVERSITY OF SURREY; ROBERTS, LISA, ORIEL; BELSHAM, GRAHAM, JOHN) 14 February 2002 (2002-02-14)
- D2: TOTH R L ET AL: "A novel strategy for the expression of foreign genes from plant virus vectors" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 489, no. 2-3, 2 February 2001 (2001-02-02), pages 215-219, XP004248888 ISSN: 0014-5793
- D3: WO 02/29068 A (ICON GENETICS AG; GLEBA, YURI; DOROKOV, YURII; IVANOV, PETER; ATABEKOV) 11 April 2002 (2002-04-11)

D1, which is considered to represent the most relevant state of the art, discloses a method of conferring disease resistance to a transgenic plant using a construct comprising an internal ribosome entry site (IRES).

D2 discloses a method for expressing heterologous genes in transgenic plant using an IRES or its complementary sequence.

D3 discloses methods for expressing heterologous genes -in either sense or antisense orientation- in transgenic plants using an IRES.

The subject-matter of claim 1 is therefore new (Article 33(2) PCT). The same holds true for claims 2-235.

The problem to be solved by the present invention may be regarded as the provision of an alternative method for conferring disease resistance to a transgenic plant.

The solution is the provision of a method in using a sequence complementary to a coding sequence for a heterologous resistance gene in combination with a sequence complementary to an IRES.

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/US2004/021451

The solution to this problem proposed in claim 1 of the present application is considered as involving an inventive step (Article 33(3) PCT) for the following reasons:

None of the cited prior art documents discloses nor suggests the use of a sequence complementary to a coding sequence for a heterologous resistance gene in combination with a sequence complementary to an IRES.

The same applies mutatis mutandis to the independent claims 30, 73, 119, 135, 137, 141, 142, 152, 154, 158, 159, 169, 175, 176, 196, 216. The dependent claims as such also meet the requirements of the PCT with respect to novelty and inventive step.